How do we keep mRNA-LNP vaccines stable without ultra-cold freezers? A recent study, "Formulation screening of lyophilized mRNA-lipid nanoparticles," by Dr. Andrea Allmendinger and her team at the University of Freiburg, Germany, explores how specific excipients can extend mRNA-LNP shelf-life beyond the cold chain.

Key Findings:
• Combining 9% trehalose with 1% PVP preserved mRNA-LNP size, polydispersity index, and encapsulation efficiency for up to 6 months at 25?°C.
• Sucrose-based formulations failed at higher temperatures, while trehalose-PVP systems maintained cake integrity and transfection potency.
• Protectants added inside the LNPs (during mixing) performed comparably to those added externally, opening new formulation strategies.

Why It Matters:
This research could pave the way for room-temperature stable mRNA therapeutics, eliminating cold chain logistics and dramatically improving global access. It also lays the groundwork for future formulation designs that ensure robust long-term stability.

Read more: https://doi.org/10.1016/j.ijpharm.2025.125272